All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 27th April 2017, the European Medicines Agency (EMA) granted Orphan Drug Designation status to PQR309 for the treatment of patients with DLBCL.
PIQUR Therapeutics AG’s PQR309 is an oral, brain-penetrant, dual inhibitor of the PI3K/mTOR pathway. It can cross the blood-brain barrier, making it an attractive choice in treating malignant diseases involving the brain.
PQR309 has shown pre-clinical activity in various tumor models, as well as clinical activity in phase I and II studies. The dual PI3K/mTOR pathway inhibitor is currently being investigated in a phase I/II trial (NCT02249429) and a phase II trial (NCT03127020) in R/R lymphoma, as well as two phase II trials in R/R PCNSL (NCT02669511; NCT03120000).
Currently, PQR309 already holds an Orphan Drug Designation for patients with Primary Central Nervous System Lymphoma (PCNSL), granted by the U.S. Food and Drug Administration (FDA) in December 2016.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox